Skip to content Skip to footer
Subscribe Now
Exclusive_Chris Heery_2024
EXCLUSIVE

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM)  Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma  In late 2022,…
September 30, 2024

Read more

Exclusive_Moitreyee Chatterjee-Kishore_2024
EXCLUSIVE

Decoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots

Shots:  Recently EC granted Marketing Authorization to Astellas’ VYLOY (zolbetuximab) in combination with chemotherapy for the treatment of patients with advanced gastric and GEJ cancers  Zolbetuximab, a monoclonal antibody designed to target gastric tumor cells that express CLDN18.2 biomarker  Today, at PharmaShots we have Dr. Moitreyee Chatterjee-Kishore the Head of Development, Immuno-Oncology and Cancer Cell…
September 26, 2024

Read more

Viewpoints_Sofie Berg
VIEWPOINTS

Unlocking Approval: Sofie Berg from AbbVie in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Recently, the European Commission approved AbbVie’s Skyrizi for the treatment of adults with moderate to severe active Ulcerative Colitis  The approval was based on positive data from the P-III INSPIRE induction trial and COMMAND maintenance study   Today, at PharmaShots we have Sofie Berg, the therapeutic area head of international immunology, International Medical Affairs, at…
September 23, 2024

Read more

Viewpoints_Jacqueline Nielsen_Tahi Ahmadi
VIEWPOINTS

Unlocking Approval: Jacqueline Nielsen from AbbVie & Tahi Ahmadi from Genmab in a Riveting Conversation with PharmaShots

Shots:  Recently, the EMA’s CHMP adopted a positive opinion by recommending conditional marketing authorization for AbbVie and Genmab’s Tepkinly for the treatment of R/R Follicular Lymphoma  Today at PharmaShots, we have Jacqueline Nielsen, Head of Hematologic Oncology Affairs at AbbVie, and Tahi Ahmadi, EVP and CMO at Genmab, shedding light on this conditional marketing authorization…
September 18, 2024

Read more

Viewpoints_Ahsan Arozullah
VIEWPOINTS

Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

Shots:  At ASCO 2024, Astellas Pharma presented 16 abstracts across several types of cancers with unmet medical needs  Today at PharmaShots, we have Ahsan Arozullah Sr. VP, Head of Oncology Development, shedding light on the advancement Astellas’ oncology portfolio for urothelial carcinoma, gastric cancer, and prostate cancer  Ahsan talks about the presented results from studies…
September 16, 2024

Read more

Viewpoints_Christophe Piketty
VIEWPOINTS

Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

Shots:  Atopic dermatitis remains one of the most common inflammatory skin diseases, affecting more than 230M people across the globe. Characterized by frequent itching and recurrent skin lesions, atopic dermatitis is a chronic condition  Recently the Lancet published data from Galderma’s P-III trial, ARCADIA 1 and ARCADIA 2, demonstrating the potential of nemolizumab to improve skin…
September 11, 2024

Read more

Viewpoints_Hjalte Hojsgaard
VIEWPOINTS

Unlocking Innovation: Hjalte Hojsgaard from Insulet Corporation in Dialogue Exchange with PharmaShots

Shots:  Recently, Insulet announced the commercial launch of Omnipod 5 Automated Insulin Delivery System in the UK and Netherlands  Omnipod 5 is a tubeless AID system that communicates with a continuous glucose monitor (CGM), proactively correcting for highs and protecting against lows every five minutes, day and night  Today at PharmaShots, we have Hjalte Hojsgaard,…
September 9, 2024

Read more

Viewpoints_Piotr Trzonkowski
VIEWPOINTS

Enhancing Care: Piotr Trzonkowski from PolTREG in an Interesting Dialogue Exchange with PharmaShots

Shots:   Recently, PolTREG announced positive long-term follow-up data for PTG-007 from the P-I/II studies for early-onset type 1 diabetes  PolTREG develops therapies using T-regulatory cells for autoimmune diseases. With the positive results, PolTREG has met EMA’s requirement to confirm the safety of Treg therapies at least five years after the administration  Today, at PharmaShots, we…
September 4, 2024

Read more

Exclusive_Ahsan Arozullah_2024
EXCLUSIVE

Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

Shots:  Recently, the CHMP of the EMA adopted a positive opinion for Astellas’ Padcev + Keytruda combination therapy as the first-line treatment of patients with unresectable or metastatic urothelial cancer  Today, in an exclusive coverage, we bring an enlightening conversation with Ahsan Arozullah from Astellas Pharma, sharing insights from the P-III EV-302 study  Astellas looks…
September 4, 2024

Read more

Load more